The information provided on the teleconference is only accurate at the time of the conference call, and Monogram assumes no obligation to provide updated information except as required by law.
Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.
Forward Looking Statements
Certain statements in this press release are forward-looking. These
forward-looking statements include references to the demand for our Trofile
Assay, the potential use of our Trofile Assay for patient selection for
maraviroc, the size and timing of clinical trials utilizing our products,
the outlook for maraviroc and our Trofile Assay, the number of patients
each year in the U.S. who potentially could be candidates for new classes
of HIV drugs such as maraviroc, the ability of VeraTag technology to
significantly improve the information available to physicians, results of
studies intended to demonstrate clinical utility of our VeraTag technology
and products and anticipated clinical and laboratory validation of VeraTag
in a CLIA setting, expected protection provided by patents, possible
regulation of Trofile an
|SOURCE Monogram Biosciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved